Relapsed Refractory Large B-Cell Lymphoma Treatment Market

Second-line therapy leads the relapsed refractory large B-cell lymphoma treatment market with a 40.4% share in 2026, followed by hospitals at 33.7% by end user and CAR-T cell therapy at 33.4% by therapy type. Adoption reflects growing use of advanced therapies, while high treatment costs and patient eligibility requirements remain key constraints.